Cerebral Oximetry to Reduce Organ Dysfunction After Non-cardiac Surgery

Surgery Clinical Trial

Official title:

Role of Cerebral Oximetry In Reducing Postoperative End Organ Dysfunction/Failure After Complex Non- Cardiac Surgery

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03861026
• Other study ID #: 16-5747
• Status: Recruiting
• Phase: N/A
• Start date: October 5, 2018
• Est. completion date: May 28, 2021

Study information

• Verified date: December 2020
• Source: University Health Network, Toronto
• Contact: George Djaiani
• Phone: 416-340-4800
• Email: george.djaiani[@]uhn.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Number of elderly patients requiring general anesthesia for major surgical procedures is increasing dramatically. It is estimated that 20% of these patients will develop major complications after surgery. Monitoring brain oxygen saturation may be helpful in reducing the postoperative complication rates. A decrease in brain oxygen is a sign that all other vital organs such as kidneys, heart, liver, and intestines have reduced blood supply and are starved from oxygen. This happens in 1 out of 5 patients undergoing major complex surgeries. Brain oxygen saturation monitor at this time is not used routinely during surgery, primarily due to the added cost, as well as, insufficient evidence that restoring the brain oxygen saturation to baseline would result in better outcomes. Patients will be randomly assigned to either study or control groups. In the study group, a special algorithm will be used to restore brain oxygen saturation. In the control group, the brain oxygen saturation will be monitored continuously, but the monitor screen will be electronically blinded, and standard clinical care applied. The objective of this study is to see if restoring the brain oxygen saturation to baseline results in less complication rates after surgery.

The objective of this study is to reduce the incidence of postoperative morbidity due to end organ dysfunction after major non-cardiac surgery in elderly patients.

The primary aim is to determine if restoration of rSO2 to baseline levels results in reduced incidence of major organ morbidity and mortality (MOMM).

A secondary aim is to determine a cost-effectiveness of this monitoring modality.

Description:

The investigator will collect delirium, stroke, transient ischemic attacks, myocardial infarction (troponin essays), pulmonary embolism (clinical, echocardiography and computer tomography assessments), renal failure (creatinine increase by at least 50% from baseline), pneumonia (clinical, X-ray), atrial fibrillation (documented electrocardiogram), bleeding requiring a transfusion of more than or equal to 4 units of red blood cells within 72 hours of surgery, mechanical ventilation for 2 days, major wound disruption, surgical site infection, sepsis, septic shock, systemic inflammatory response syndrome (vasoactive medication requirement), unplanned return to the operating room, and vascular graft failure, for the duration of hospital stay, as well as, all-cause 30-day mortality. Frailty scale & DASI questionnaires will be administered at screening visit. Postoperative quality of recovery score (QoR-15) with be performed at baseline, POD 1 & 5 (discharge if earlier)]. Disability Free Survival (DFS) at 6 months (administer WHODAS).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 394
• Est. completion date: May 28, 2021
• Est. primary completion date: May 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Patients > 60 years of age

• Undergoing elective major non-cardiac surgery with an anticipated surgical duration of 4 hours or more,

• Preoperative written informed consent.

Exclusion Criteria:

• Emergency surgery

• Laparoscopic/Robotic surgery

Related Conditions & MeSH terms

• Cerebral Desaturation
• Surgery

Intervention

Device:
• Bilateral NIRS (Masimo, O3TM Regional Oximetry)
Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.

Locations

Country	Name	City	State
Canada	Tornoto General Hospital, University Health Network	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	A composite outcome of major end organ dysfunction	A composite outcome will be assessed as a dichotomous outcome. (YES or NO). All components of the composite outcome will be weighted equally. They will include the following outcomes: postoperative delirium assessed with Confusion Assessment Method (CAM), Stroke assessed clinically, Transient Ischemic Attacks assessed clinically, Myocardial infarction, Pulmonary Embolism, Renal failure, Pneumonia, Atrial fibrillation, bleeding, mechanical ventilation for =48 hours, Major wound disruption, Surgical site infection, Sepsis, Septic shock, Systemic inflammatory response syndrome, Vascular graft failure. Frailty scale & DASI questionnaires will be administered at screening visit.; Postoperative quality of recovery score (QoR-15) with be performed at baseline, POD 1 & 5 (discharge if earlier)]. Disability Free Survival (DFS) at 6 months (WHODAS).	surgery date to 6 months post surgery